Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $30.00.

A number of research firms have weighed in on KYTX. JPMorgan Chase & Co. cut their price objective on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Wednesday, June 24th. HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of Kyverna Therapeutics in a research note on Wednesday, June 3rd. Finally, Wall Street Zen cut Kyverna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th.

Kyverna Therapeutics Price Performance

Shares of NASDAQ KYTX opened at $7.41 on Monday. The company has a market cap of $450.49 million, a PE ratio of -2.26 and a beta of 1.87. Kyverna Therapeutics has a fifty-two week low of $2.80 and a fifty-two week high of $13.67. The company has a debt-to-equity ratio of 0.13, a quick ratio of 8.15 and a current ratio of 8.15. The business has a 50-day simple moving average of $8.27 and a two-hundred day simple moving average of $8.54.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its earnings results on Tuesday, May 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.09. As a group, equities analysts expect that Kyverna Therapeutics will post -2.78 EPS for the current fiscal year.

Institutional Investors Weigh In On Kyverna Therapeutics

Several large investors have recently bought and sold shares of the company. Public Employees Retirement System of Ohio acquired a new stake in Kyverna Therapeutics during the 3rd quarter worth $28,000. Qube Research & Technologies Ltd purchased a new stake in Kyverna Therapeutics in the 2nd quarter valued at $43,000. Rhumbline Advisers increased its stake in shares of Kyverna Therapeutics by 22.0% in the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock worth $61,000 after acquiring an additional 5,694 shares during the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of Kyverna Therapeutics in the 3rd quarter worth $77,000. Finally, Bank of America Corp DE raised its holdings in shares of Kyverna Therapeutics by 41.6% during the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after acquiring an additional 6,400 shares during the period. 18.08% of the stock is currently owned by hedge funds and other institutional investors.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.